Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The company’s discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. Its product pipeline includes second- and third-generation programs in HIV maturation inhibition. The company was founded in 1999 and is headquartered in Watertown, Massachusetts.

The National Health Laboratory Service (NHLS) is a South African national government institution established in 2001. It was created by merging the South African Institute for Medical Research (SAIMR), the National Centre for Occupational Health and the National Institute for Virology. It also absorbed various provincial health department and university-run pathology laboratories.

Science & Technology Corp. provides scientific, technical, and engineering services. The firm Specializes in defense chemical and biological research, test and evaluation, range support services, earth and space sciences, polar technologies, aerospace engineering and information systems engineering and support. The company was founded in 1979 and is headquartered in Hampton, VA.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

CAPRISA ("Centre for the AIDS Programme of Research in South Africa") is the name of an AIDS research center based in Durban, South Africa.

Los Alamos National Security LLC is an American private company located in Los Alamos, NM. The firm provides research, development and testing services.

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

Ramot at Tel Aviv University Ltd. operates as a technology transfer company of Tel Aviv University (TAU). It provides legal and commercial frameworks for inventions made by TAU faculty, students, and researchers. The firm licenses the university's intellectual property to third parties through agreements; facilitates collaborative research partnerships between business partners and TAU researchers; establishes a company; and forms joint ventures that promote TAU technologies. The company was founded in 1973 and is headquartered in Tel Aviv, Israel.

Vir Biotechnology is a commercial-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases. The company brings together cutting-edge innovations with scientific expertise and management. It seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. Vir Biotechnology also focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company four current technology platforms are designed to, either individually or in combination, stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Their vision is that one day, diseases like hepatitis B, influenza A, HIV, and tuberculosis become a thing of the past.

Humabs currently has two clinical-stage partnered programs, validating the CellClone technologies and generating a significant revenue stream Humabs has a broad partnership with MedImmune, the global biologics research and development arm of AstraZeneca, that covers multiple pathogens. The most advanced of the projects is an antibody directed against influenza A virus. This antibody, called MEDI8852, has demonstrated activity against all known subtypes of the influenza A virus and is therefore less affected by the emergence of new strains. The program was partnered with MedImmune while still in preclinical development and has currently concluded the clinical phase 1b/2a. Data on this program have been published in the journals Science and Cell. Humabs has also partnered with Novartis for an antibody directed against an undisclosed target. This program is currently in phase 2.

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. INOVIO is the first and only company to have clinically demonstrated that DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, demonstrated it destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 90% of anal cancer, and 69% of vulvar cancer.

The United States Department of Veterans Affairs (VA) is a federal Cabinet-level agency that provides near-comprehensive healthcare services to eligible military veterans at VA medical centers and outpatient clinics located throughout the country; several non-healthcare benefits including disability compensation, vocational rehabilitation, education assistance, home loans, and life insurance; and provides burial and memorial benefits to eligible veterans and family members at 135 national cemeteries.

Cornell provides education about the earth and atmospheric sciences. They offer summer and winter sessions. Their students contact them through phone and email services.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Molsoft is a leading provider of tools, databases and consulting services in the area of structure prediction, structural proteomics, bioinformatics, cheminformatics, molecular visualization and animation, and rational drug design. Molsoft offers complete solutions customized for a biotechnology or pharmaceutical company in the areas of computational biology and chemistry. Molsoft is committed to continuous innovation, scientific excellence, the development of the cutting edge technologies and original ideas. Molsoft offers software tools and services in lead discovery, modeling, cheminformatics, bioinformatics, and corporate data management; and forms partnerships with biotechnology and pharmaceutical companies. MolSoft is building unique technologies for structure prediction that improves their understanding of the spatial organization of biological molecules and their interactions with each other, their biological substrates and drug-like molecules at the atomic level.

Integrated BioTherapeutics is a biotechnology company that focuses on discovering novel vaccines and therapeutics for emerging infectious diseases. Its antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines, and a variety of other product candidates for emerging viruses.